PL2714006T3 - Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu - Google Patents

Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu

Info

Publication number: PL2714006T3
Authority: PL; Poland
Prior art keywords: gel formulations; adhesive gel; treating male; intranasal testosterone; male hypogonadism
Prior art date: 2011-05-15

Application number

PL12748245T

Other languages

English (en)

Other versions

PL2714006T4 (pl

Inventor

Wayne KREPPNER

Siobhan Fogarty

Werner Oberegger

Paul José Pierre Marie Maes

Original Assignee

Acerus Biopharma Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-15

Filing date

2012-05-15

Publication date

2021-08-16

2012-05-15 Application filed by Acerus Biopharma Inc. filed Critical Acerus Biopharma Inc.

2021-08-16 Publication of PL2714006T3 publication Critical patent/PL2714006T3/pl

2021-08-16 Publication of PL2714006T4 publication Critical patent/PL2714006T4/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Otolaryngology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pregnancy & Childbirth (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)

PL12748245T 2011-05-15 2012-05-15 Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu PL2714006T4 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201161486324P	2011-05-15	2011-05-15
US201161486634P	2011-05-16	2011-05-16
EP12748245.3A EP2714006B1 (en)	2011-05-15	2012-05-15	Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
PCT/IB2012/001112 WO2012156820A1 (en)	2011-05-15	2012-05-15	Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Publications (2)

Publication Number	Publication Date
PL2714006T3 true PL2714006T3 (pl)	2021-08-16
PL2714006T4 PL2714006T4 (pl)	2021-08-16

Family

ID=46579248

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12748245T PL2714006T4 (pl)	2011-05-15	2012-05-15	Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu

Country Status (16)

Country	Link
EP (3)	EP2714006B1 (pl)
JP (9)	JP2014513716A (pl)
KR (9)	KR20200028503A (pl)
CN (4)	CN103813784A (pl)
AR (2)	AR089553A1 (pl)
AU (11)	AU2012257492A1 (pl)
BR (2)	BR112013029336B1 (pl)
CA (3)	CA3034552C (pl)
DK (1)	DK2714006T3 (pl)
EA (1)	EA201391701A1 (pl)
ES (1)	ES2859784T3 (pl)
IL (2)	IL229401A0 (pl)
MX (4)	MX363561B (pl)
PL (1)	PL2714006T4 (pl)
WO (2)	WO2012156822A1 (pl)
ZA (2)	ZA201309264B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
CA3034552C (en) *	2011-05-15	2023-02-07	Acerus Biopharma Inc.	Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
US8971800B2 (en) *	2011-05-31	2015-03-03	Qualcomm Incorporated	Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
EP2782584B1 (en)	2011-11-23	2021-06-09	TherapeuticsMD, Inc.	Natural combination hormone replacement formulations and therapies
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20150297733A1 (en) *	2012-11-14	2015-10-22	Trimel Biopharma Srl	Controlled release topical testosterone formulations and methods
WO2014093818A2 (en) *	2012-12-14	2014-06-19	Bioject, Inc.	Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
ES2749588T3 (es) *	2013-10-07	2020-03-23	Antares Pharma Inc	Modulación de hematocrito mediante inyección de testosterona a chorro asistida por aguja
EP3107547A4 (en) *	2014-02-19	2017-11-15	Antares Pharma, Inc.	Needle assisted jet injection administration of testosterone compositions
CA2947767A1 (en)	2014-05-22	2015-11-26	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
WO2016018993A1 (en)	2014-07-29	2016-02-04	Therapeuticsmd, Inc.	Transdermal cream
WO2016123317A1 (en) *	2015-01-28	2016-08-04	Prometheon Pharma, Llc	Topical formulations of growth factors
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
BR102015020878B1 (pt) *	2015-08-28	2019-08-27	F B M Ind Farmaceutica Ltda	formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
BR122023025444A2 (pt) *	2016-01-07	2024-02-20	Viramal Limited	Composição de gel estável, e, método de preparação de uma composição em gel estável
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US10286077B2 (en)	2016-04-01	2019-05-14	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
JP2019514504A (ja)	2016-04-25	2019-06-06	コスカファミリーリミテッド	薬剤送達システム
WO2017208072A2 (en) *	2016-06-02	2017-12-07	Acerus Pharmaceutical Corporation	Nasal cannabidiol compositions
CA3026041A1 (en)	2016-06-03	2017-12-07	M et P Pharma AG	Nasal pharmaceutical compositions with a porous excipient
RU2019123307A (ru)	2017-01-20	2021-02-20	М Эт П Фарма Аг	Фармацевтические композиции для назального введения для снижения рисков воздействия загрязнителей воздуха
KR102164230B1 (ko) *	2017-06-17	2020-10-12	엘지전자 주식회사	무선 통신 시스템에서 단말의 등록 방법 및 이를 위한 장치
AU2018371435B2 (en) *	2017-11-27	2023-12-14	Aska Pharmaceutical Co., Ltd.	Powder preparation for nasal administration
BR112020015650A2 (pt) *	2018-02-02	2020-12-08	Aytu Bioscience, Inc.	Métodos de terapia de testosterona
WO2019175290A1 (en)	2018-03-13	2019-09-19	Beckley Canopy Therapeutics Limited	Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
CN108771622B (zh) *	2018-07-11	2022-01-07	尹振图	一种自闭式针形滴嘴及眼药水瓶
CA3117842A1 (en)	2018-10-26	2020-04-30	Viramal Limited	Mucoadhesive gel composition
EP3659583B1 (en)	2018-11-30	2023-06-07	Viramal Limited	A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
EA202191378A1 (ru) *	2018-12-14	2021-10-04	Ацерус Биофарма Инк.	Активные сложноэфирные производные тестостерона, их композиции и применения
JP7508035B2 (ja)	2020-03-10	2024-07-01	オムロン株式会社	電子機器及び近接センサ
CN112121049B (zh) *	2020-08-28	2022-02-01	嘉兴市第一医院	顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
IL302986A (en) *	2020-11-19	2023-07-01	Acousia Therapeutics Gmbh	A non-aqueous gel preparation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4082881A (en) *	1976-12-23	1978-04-04	E. R. Squibb & Sons, Inc.	Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de)	1992-05-06	1995-05-18	Arrowdean Ltd	Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en)	1992-06-03	1998-05-26	Arrowdean Limited	Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) *	1994-02-18	1995-08-24	Schering Ag	Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en)	1994-11-08	1996-11-19	Micron Technology, Inc.	Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) *	1997-07-03	2000-10-24	アルザコーポレイション	ドラッグデリバリーディバイスとその製造法
DK1510213T3 (da) *	1997-11-10	2009-03-23	Strakan Int Ltd	Penetrationsforbedrende og irritationsreducerende systemer omfattende testosteron
US20040198706A1 (en) *	2003-03-11	2004-10-07	Carrara Dario Norberto R.	Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) *	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) *	2000-12-23	2002-07-11	Impetus Ag Basel	Thixotropes Nasenspray
CA2463384A1 (en) *	2001-10-12	2003-04-17	Cns, Incorporated	Hydrating nasal gel and applicator
MY139721A (en) *	2002-04-19	2009-10-30	Cpex Pharmaceuticals Inc	Pharmaceutical composition
IL152575A (en) *	2002-10-31	2008-12-29	Transpharma Medical Ltd	A skin-to-skin transmission system of water-insoluble drugs
JP5619337B2 (ja) *	2003-10-10	2014-11-05	フェリングビー．ブイ．	皮膚残渣を最小限に抑えるための経皮的医薬製剤
EP1530965B1 (en)	2003-11-11	2006-03-08	Mattern, Udo	Controlled release delivery system of sexual hormones for nasal application
CA2591296A1 (en) *	2004-12-09	2006-06-15	Bayer Healthcare Ag	Stabilisation of glucocorticoid esters with acids
JP5401092B2 (ja) *	2005-06-03	2014-01-29	アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド	経皮的薬物送達のための方法および組成物
EP1790343A1 (en) *	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) *	2006-07-06	2008-01-09	上海富海科申药业有限公司	能够减少皮肤刺激的睾酮凝胶制剂
BRPI0717509B8 (pt) *	2006-10-04	2021-05-25	M&P Patent Ag	sistema de liberação controlada para aplicação nasal de neurotransmissores
JP2010521519A (ja) *	2007-03-23	2010-06-24	ユニメッド・ファーマシューティカルズ・エルエルシー	小児性腺機能低下症の治療用組成物及び治療方法
CN101801388B (zh) *	2007-09-20	2012-07-04	株式会社资生堂	透皮吸收制剂
HUE027440T2 (en) *	2007-11-13	2016-10-28	Curadis Gmbh	C-19 steroids for specific medical applications
GB0807605D0 (en) *	2008-04-28	2008-06-04	Diurnal Ltd	Lipid composition
CA3034552C (en) *	2011-05-15	2023-02-07	Acerus Biopharma Inc.	Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

2012
- 2012-05-15 CA CA3034552A patent/CA3034552C/en active Active
- 2012-05-15 KR KR1020207006630A patent/KR20200028503A/ko active Application Filing
- 2012-05-15 MX MX2013013388A patent/MX363561B/es unknown
- 2012-05-15 EP EP12748245.3A patent/EP2714006B1/en active Active
- 2012-05-15 CN CN201280035162.8A patent/CN103813784A/zh active Pending
- 2012-05-15 MX MX2013013369A patent/MX2013013369A/es unknown
- 2012-05-15 AU AU2012257492A patent/AU2012257492A1/en not_active Abandoned
- 2012-05-15 KR KR1020137033181A patent/KR20140045400A/ko active Application Filing
- 2012-05-15 ES ES12748245T patent/ES2859784T3/es active Active
- 2012-05-15 CN CN201811198846.5A patent/CN109481394B/zh active Active
- 2012-05-15 DK DK12748245.3T patent/DK2714006T3/da active
- 2012-05-15 JP JP2014510900A patent/JP2014513716A/ja active Pending
- 2012-05-15 KR KR1020237008221A patent/KR20230041081A/ko not_active Application Discontinuation
- 2012-05-15 JP JP2014510901A patent/JP6152092B2/ja not_active Expired - Fee Related
- 2012-05-15 EP EP21191386.8A patent/EP3977982A1/en not_active Withdrawn
- 2012-05-15 PL PL12748245T patent/PL2714006T4/pl unknown
- 2012-05-15 CN CN201910982324.2A patent/CN110613679A/zh active Pending
- 2012-05-15 KR KR1020137033180A patent/KR20140033408A/ko not_active Application Discontinuation
- 2012-05-15 CN CN201280035150.5A patent/CN103796636B/zh not_active Expired - Fee Related
- 2012-05-15 KR KR1020187038088A patent/KR102088038B1/ko active IP Right Grant
- 2012-05-15 KR KR1020217036024A patent/KR20210135003A/ko not_active Application Discontinuation
- 2012-05-15 WO PCT/IB2012/001127 patent/WO2012156822A1/en active Application Filing
- 2012-05-15 KR KR1020207028301A patent/KR20200118228A/ko active Application Filing
- 2012-05-15 BR BR112013029336-5A patent/BR112013029336B1/pt active IP Right Grant
- 2012-05-15 CA CA2836398A patent/CA2836398C/en active Active
- 2012-05-15 KR KR1020197029484A patent/KR20190117803A/ko not_active Application Discontinuation
- 2012-05-15 BR BR112013029332-2A patent/BR112013029332A2/pt not_active Application Discontinuation
- 2012-05-15 MX MX2020008599A patent/MX2020008599A/es unknown
- 2012-05-15 EA EA201391701A patent/EA201391701A1/ru unknown
- 2012-05-15 AU AU2012257490A patent/AU2012257490A1/en not_active Abandoned
- 2012-05-15 WO PCT/IB2012/001112 patent/WO2012156820A1/en active Application Filing
- 2012-05-15 CA CA2836405A patent/CA2836405C/en active Active
- 2012-05-15 EP EP12738595.3A patent/EP2709588B1/en active Active
- 2012-05-15 KR KR1020217007047A patent/KR102568894B1/ko active IP Right Grant
- 2012-05-16 AR ARP120101721A patent/AR089553A1/es not_active Application Discontinuation
- 2012-05-16 AR ARP120101720A patent/AR086409A1/es not_active Application Discontinuation
2013
- 2013-11-11 IL IL229401A patent/IL229401A0/en unknown
- 2013-11-11 IL IL229400A patent/IL229400A0/en unknown
- 2013-11-15 MX MX2019003340A patent/MX2019003340A/es active IP Right Grant
- 2013-12-09 ZA ZA2013/09264A patent/ZA201309264B/en unknown
- 2013-12-09 ZA ZA2013/09265A patent/ZA201309265B/en unknown
2017
- 2017-03-22 JP JP2017056679A patent/JP6594924B2/ja not_active Expired - Fee Related
- 2017-05-24 AU AU2017203470A patent/AU2017203470A1/en not_active Abandoned
- 2017-06-20 AU AU2017204182A patent/AU2017204182A1/en not_active Abandoned
2018
- 2018-08-27 JP JP2018158566A patent/JP2018199701A/ja active Pending
2019
- 2019-03-08 AU AU2019201618A patent/AU2019201618A1/en not_active Abandoned
- 2019-04-30 AU AU2019203067A patent/AU2019203067A1/en not_active Abandoned
- 2019-05-15 AU AU2019203400A patent/AU2019203400A1/en not_active Abandoned
- 2019-09-25 JP JP2019173990A patent/JP7017254B2/ja active Active
2020
- 2020-01-29 JP JP2020012807A patent/JP2020079257A/ja active Pending
- 2020-07-29 AU AU2020210227A patent/AU2020210227A1/en not_active Abandoned
- 2020-09-18 JP JP2020157216A patent/JP2021001206A/ja active Pending
- 2020-11-09 AU AU2020267162A patent/AU2020267162B2/en not_active Ceased
2022
- 2022-03-07 JP JP2022034334A patent/JP2022078222A/ja active Pending
- 2022-04-12 AU AU2022202402A patent/AU2022202402A1/en not_active Abandoned
- 2022-05-06 JP JP2022076671A patent/JP2022105175A/ja active Pending
2024
- 2024-08-23 AU AU2024216312A patent/AU2024216312A1/en active Pending

Also Published As

Publication number	Publication date
AR086409A1 (es)	2013-12-11
AR089553A1 (es)	2014-09-03
AU2020267162A1 (en)	2020-12-03
AU2017204182A1 (en)	2017-07-20
KR20210029849A (ko)	2021-03-16
BR112013029336A2 (pt)	2020-08-11
AU2020210227A1 (en)	2020-08-20
CN110613679A (zh)	2019-12-27
CN109481394A (zh)	2019-03-19
BR112013029336B1 (pt)	2021-11-30
IL229401A0 (en)	2014-01-30
KR20200118228A (ko)	2020-10-14
EP2709588A1 (en)	2014-03-26
EP2714006B1 (en)	2020-12-09
MX2020008599A (es)	2022-08-31
AU2012257490A1 (en)	2013-12-19
CA2836398C (en)	2021-12-14
CN103813784A (zh)	2014-05-21
AU2019203067A1 (en)	2019-05-23
MX2013013369A (es)	2014-10-17
KR20200028503A (ko)	2020-03-16
CA3034552C (en)	2023-02-07
AU2019201618A1 (en)	2019-04-18
IL229400A0 (en)	2014-01-30
AU2022202402A1 (en)	2022-05-12
AU2012257492A1 (en)	2013-12-19
AU2019203400A1 (en)	2019-08-01
JP2014515038A (ja)	2014-06-26
JP7017254B2 (ja)	2022-02-08
KR20140045400A (ko)	2014-04-16
JP2018199701A (ja)	2018-12-20
WO2012156822A1 (en)	2012-11-22
KR20190006194A (ko)	2019-01-17
JP6152092B2 (ja)	2017-06-28
PL2714006T4 (pl)	2021-08-16
CA3034552A1 (en)	2012-11-22
AU2020267162B2 (en)	2022-06-09
JP2022105175A (ja)	2022-07-12
JP2021001206A (ja)	2021-01-07
MX2013013388A (es)	2014-09-15
CA2836398A1 (en)	2012-11-22
KR20210135003A (ko)	2021-11-11
JP2020079257A (ja)	2020-05-28
KR20230041081A (ko)	2023-03-23
AU2024216312A1 (en)	2024-10-24
JP2022078222A (ja)	2022-05-24
CN103796636B (zh)	2019-04-05
JP2014513716A (ja)	2014-06-05
CN103796636A (zh)	2014-05-14
EP3977982A1 (en)	2022-04-06
JP2017160204A (ja)	2017-09-14
KR102568894B1 (ko)	2023-08-21
CA2836405C (en)	2021-09-07
EP2714006A1 (en)	2014-04-09
MX363561B (es)	2019-03-27
JP6594924B2 (ja)	2019-10-23
ZA201309264B (en)	2015-09-30
ZA201309265B (en)	2016-01-27
JP2020073469A (ja)	2020-05-14
WO2012156820A9 (en)	2014-02-20
DK2714006T3 (da)	2021-03-15
BR112013029332A2 (pt)	2021-06-01
CN109481394B (zh)	2023-05-05
KR20190117803A (ko)	2019-10-16
KR20140033408A (ko)	2014-03-18
WO2012156820A1 (en)	2012-11-22
ES2859784T3 (es)	2021-10-04
AU2017203470A1 (en)	2017-06-22
KR102088038B1 (ko)	2020-03-13
CA2836405A1 (en)	2012-11-22
EP2709588B1 (en)	2021-08-25
EA201391701A1 (ru)	2014-04-30
MX2019003340A (es)	2019-07-04

Publication	Publication Date	Title
ZA201309265B (en)	2016-01-27	Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
HK1255929A1 (zh)	2019-09-06	前體脂質體睾酮製劑
HK1206776A1 (en)	2016-01-15	Improved cleaning formulation and method
EP2655334A4 (en)	2014-12-31	COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL218020A0 (en)	2012-04-30	Devices and methods for dressing applicators
EP2558120A4 (en)	2013-08-28	METHOD AND COMPOSITION FOR INTRANASAL ADMINISTRATION
EP2647091A4 (en)	2016-01-27	SYSTEM AND METHOD FOR LASER CHARACTERIZATION
IL228557A0 (en)	2013-12-31	Solar absorbing formulations and related devices and methods
EP2544655A4 (en)	2014-05-14	COMPOSITIONS AND METHODS FOR TREATING SKIN
HUE044816T2 (hu)	2019-11-28	Készítmények és eljárások hajhullás kezelésére
ZA201305665B (en)	2014-03-26	Testosterone formulations
EP2575825A4 (en)	2014-01-01	COMPOSITIONS AND METHODS FOR TREATING DEPRESSION
EP2689770A4 (en)	2015-05-27	DAMAGED HAIR CARE AND METHOD FOR IMPROVING THE CONDITION OF DAMAGED HAIR THEREWITH
PT2608766E (pt)	2015-03-05	Processo e kit para o tratamento do cabelo
EP2590674A4 (en)	2014-09-10	COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
IL229322A0 (en)	2014-01-30	Low strength testosterone intranasal gel preparations and their use for the treatment of anorgasmia or libido disorder
GB2490787B (en)	2015-02-11	Compact broadband source and method
HK1198137A1 (en)	2015-03-13	Disinfecting formulations and uses thereof
GB2473297B (en)	2012-05-30	Hair extension and hair extension process
EP2557720A4 (en)	2016-04-20	DEVICE AND METHOD FOR TRANSFORMATION
EP2822578A4 (en)	2015-10-07	TISSUE CONSTRUCTS AND USES THEREOF
ZA201409028B (en)	2015-12-23	Cosmetic composition and method for using thereof
ZA201207226B (en)	2014-12-23	Compositions and methods for treating viral diseases
EP2776462A4 (en)	2015-04-08	INDOLALKYLAMINO WITHASTEROID CONJUGATES AND USE METHOD THEREFOR
EP2695604A4 (en)	2014-08-20	SPIRULIN-BASED COSMETIC COMPOSITION AND COSMETIC TREATMENT PROCESS